What do ipamorelin Aib residue HPLC retention characteristics record?
A retention characteristic is a measured chromatographic position, not a structural constant and not a residue-level assay. For an intact ipamorelin lot, the peak represents the full pentapeptide. The Aib residue is inside that molecule. It is not observed as a free amino acid unless a separate hydrolysis method is used, and that hydrolysis result is a composition test, not a reversed-phase retention time. Conflating the two is a documentation error: composition may support an alpha,alpha-disubstituted residue, while the chromatogram supports only that a UV-active species eluted at a stated position under stated conditions. The descriptive set is conditional. It names stationary-phase chemistry, column temperature, ion-pair or buffer acid, organic modifier, and whether elution was isocratic or gradient. It states detection wavelength and bandwidth. It reports the main-peak apex time and, where a qualified reference is run in the same sequence, the relative retention time. Relative retention is more transferable than an absolute time because dwell volume and gradient delay move every peak. It does not become an identity proof. A laboratory-defined window, written on the certificate, is a concordance check against that reference, not a demonstration that Aib rather than another residue of similar polarity is present. Ultraviolet detection does not see Aib as a unique chromophore. Near 214 nm the signal is dominated by the peptide bond. Near 280 nm it arises from the aromatic side chains, principally D-2-naphthylalanine and D-phenylalanine. Aib, the lysine side chain and the C-terminal amide contribute negligibly at 280 nm. A channel ratio can hint that a co-eluting non-aromatic species is inflating the 214 nm area, but it is not a residue-specific purity figure for Aib. The 1998 structural report fixes the sequence this interpretation assumes (Raun et al., 1998; PMID:9849822). It does not fix a retention time, a column or an acceptance interval.
How does N-terminal Aib differ from alanine or glycine on a reversed-phase record?
N-terminal Aib is 2-aminoisobutyric acid, or alpha-methylalanine. Both substituents on the alpha-carbon are methyl groups, so the residue has no stereocentre. Unlike glycine, it is not a methylene unit. The extra methyl group relative to alanine changes volume, backbone preference and, modestly, hydrophobicity. Those facts do not produce a fixed shift in minutes on every C18 column. On an acidic reversed-phase system, a slightly more hydrocarbon-like N-terminus tends to increase retention relative to a more polar one. Aib versus alanine is one methylene equivalent in elemental composition; Aib versus glycine is two. Whether either step is resolved depends on gradient slope, efficiency, ion-pair concentration and the naphthyl side chain, which can mask a small N-terminal difference. Observed resolution, or its absence, is reported against a qualified marker. An elution order copied from another method is not treated as established. Mass sits beside retention, not inside it. The Aib residue formula is C4H7NO; alanine is C3H5NO and glycine is C2H3NO. Substitution of Aib by alanine changes composition by CH2, about 14 Da; substitution by glycine changes it by C2H4, about 28 Da. Those gaps are large relative to ordinary peptide mass accuracy, even when the peaks overlap. The retention line can then read that the main peak was not resolved from an alanine-substitution marker, while the mass line is concordant or discordant with the Aib-containing composition. That split stops a co-elution being misread as confirmation of the N-terminus. Aib supplies no enantiomeric pair, so a chiral-phase chromatogram aimed at the N-terminus is not an Aib test. Stereochemical related substances concern histidine, naphthylalanine and phenylalanine, whose configuration is specified in the pentapeptide description (Raun et al., 1998; PMID:9849822). An epimer can share the intact mass and may or may not separate on achiral C18. Retention on C18 is not a stereochemical characteristic of Aib, and it is only an incomplete stereochemical characteristic of the rest of the chain.
Which other residues set the retention window around the main peak?
The retention window of ipamorelin is not an Aib window. The dominant non-polar element in the published pentapeptide is D-2-naphthylalanine, far more hydrophobic than Aib or phenylalanine (Raun et al., 1998; PMID:9849822). D-phenylalanine adds a second aromatic surface. Histidine and lysine add ionisable basic groups. The C-terminus is an amide, so there is no C-terminal carboxylate to enter pH and ion-pair equilibria. Under acidic peptide mobile phases, the N-terminal amine, the imidazole and the lysine side chain are protonated. Retention is then the net of naphthyl-driven adsorption and interaction with trifluoroacetate or with weaker formate or acetate modifiers. That net explains why two lots of the same sequence can differ in absolute time with no change at Aib. Trifluoroacetate concentration, gradient slope, column temperature and ligand hydrophobicity can each move the apex by more than an Aib-to-alanine shift. Phenyl or polar-embedded phases weight aromatic contact differently from C18, so impurity order can change with the phase. A note that names only HPLC retention, without phase and ion-pair acid, cannot be compared across laboratories. Class similarity is not chromatographic identity. Ghrelin-related sequences and peptidyl secretagogues have been compared because they arrange hydrophobic and basic features in similar ways (Matsumoto et al., 2001; PMID:11396951). Chain length, acylation and the presence or absence of Aib still change mass and partition. A mixture that contains more than one peptide of this class needs an identity assignment for each peak. Relative retention against an ipamorelin reference, plus intact mass or fragment ions, is the coherent pair. Peptidomimetic series make the same distinction. Non-proteinogenic and aromatic residues are varied as structural elements when ligands are characterised (Fowkes et al., 2018; PMID:30282322). Lipophilicity there is a design descriptor of a defined analogue, not a retention time that can be imported into an unrelated gradient and treated as the Aib characteristic of ipamorelin.
How are related substances at the Aib position classified on a chromatogram?
Related substances at the Aib position are read from two observations: relative position of a peak, and whether its mass matches a defined modification. The structural papers cited here do not supply those numbers. A laboratory generates them on its own method and labels them method-specific. Deletion of Aib, with the rest of the sequence intact, yields a tetrapeptide whose N-terminus is histidine. Loss of the alpha,alpha-dimethyl residue removes a small hydrocarbon contribution and changes the N-terminal ionisation. An earlier elution is plausible, not guaranteed, once ion-pairing and the new histidine terminus are considered. The mass change is clearer: a clean deletion removes a residue mass of about 85 Da (C4H7NO). Language consistent with des-Aib is reserved for cases where mass, and a marker or fragment series, agree. A lone earlier peak remains an unspecified related substance, reported with relative retention time and area percent above the reporting threshold. Substitution shifts are smaller. Aib replaced by alanine may sit close to the main peak or under it. If the method does not resolve that pair, a single-wavelength area percent overstates selectivity. The accurate statement is resolved, partially resolved, or not resolved, with the marker named beside the relative retention time. Residual protecting groups on the N-terminus or on lysine add substantial hydrophobicity and are sought late in the gradient, not in an early Aib-shift region. Retention position alone does not justify calling a late peak an Aib adduct. Response factors differ. A fragment that has lost both aromatic residues can be nearly silent at 280 nm and still contribute area at 214 nm. A deletion that has lost only Aib, but retained naphthylalanine, remains visible on both channels. A table integrated on one channel names that channel. Area percent is not an assay of Aib content, and it is not a statement about biological activity. It is a chromatographic accounting entry for a research lot.
What does a research lot record include, and what stays outside it?
A usable record of ipamorelin Aib residue HPLC retention characteristics separates observations from inferences. Observations are the method identifier, analysis date, column identifier, mobile-phase description, gradient or isocratic timetable, detection channel, main-peak apex time, reference apex time if a reference was bracketed, relative retention time, the identity window applied, and the integration events that assigned the baseline. Inferences are short: the main peak fell inside or outside the window; a named related substance was resolved or not; the chromatographic result is concordant or discordant with the orthogonal mass result. The inference does not say that the lot is suitable for any biological experiment, and it does not describe activity. Mass concordance can be stated from the published sequence without pretending that literature measured the chromatogram. Aib-His-D-2-Nal-D-Phe-Lys-NH2 corresponds to C38H49N9O5, monoisotopic mass near 711.386 Da. Agreement within the laboratory's mass tolerance supports the Aib-containing composition over an alanine or glycine substitution. Disagreement overrides a comfortable retention match. Fragment ions add sequence order. Intact mass alone does not prove that Aib is N-terminal rather than placed elsewhere, which is why a match to a qualified reference still has a role. The two results constrain different errors. System suitability belongs in the same file. Plate count, tailing and resolution from the nearest reported peak describe the peak that was integrated. They are not specifications borrowed from another peptide. A wide, tailing main peak can hide an Aib-substitution shoulder. If resolution from a marker was not shown in that run, the record says so. Silence is not selectivity. Retention does not quantify counter-ion, residual solvent, water or net peptide content. It does not locate a stability trend unless the same method was used at each time point and the comparison is written as a trend. It does not support any claim about effects in humans or animals. Research-use documentation stops at identity, purity accounting and traceability of the chromatographic conditions.
Frequently asked questions
Is Aib chiral, and can HPLC retention show an Aib enantiomer?
Aib is achiral. Both substituents on the alpha-carbon are methyl groups, so the residue has no enantiomer for a chiral stationary phase to resolve. A retention difference that is truly stereochemical would have to arise from histidine, naphthylalanine or phenylalanine, not from Aib. An achiral C18 apex time cannot be filed as an enantiomeric-purity result for the N-terminus. Configuration is taken from the stated sequence and, where the record requires it, from a separate stereochemical method. Retention characteristics of the Aib residue are therefore compositional and hydrophobic, not chiral.
Can retention time alone confirm Aib rather than alanine?
No. Aib and alanine differ by a single methylene group in elemental composition. A shallow gradient may separate them; a steep gradient, or a separation dominated by the naphthyl side chain, may not. The orthogonal discriminator is the mass difference of about 14 Da, compared with the laboratory tolerance, with a qualified marker if one was run. A retention match to an ipamorelin reference supports concordance with that reference. It does not, by itself, prove which N-terminal residue is present. Mass discordance overrides a comfortable apex-time match.
Why can 214 nm and 280 nm area percents disagree?
Aib has no aromatic chromophore. Near 214 nm, amide bonds dominate the ultraviolet signal. Near 280 nm, the signal comes from aromatic side chains, mainly naphthylalanine and phenylalanine. A fragment that has lost both aromatic residues can be weak at 280 nm and still contribute area at 214 nm. A deletion that lost only Aib, while retaining naphthylalanine, remains visible on both channels. The retention table names the channel that was integrated. The two area percentages describe different selectivity pictures and are not interchangeable.
Does a later-eluting peak mean a more hydrophobic change at Aib?
Not on position alone. Late elution can reflect a protecting-group remnant, a difference in ion-pair loading, a column or gradient change, or an unrelated hydrophobic impurity. An Aib-to-alanine substitution is a small compositional step and is sought near the main peak, not in the far late region of the gradient. Assignment uses mass, or a qualified marker, together with a stated relative retention time. A late apex without that evidence remains an unspecified related substance. Hydrophobicity is a hypothesis about the peak, not a structure.
Should one retention window be copied to every ipamorelin method?
No. Absolute time moves with dwell volume, gradient delay, temperature, ion-pair acid and stationary-phase chemistry. A window is valid for the method in which it was set, against the reference bracket used in that sequence. Another laboratory, or another column chemistry, requires its own window. What can be compared is the written method context, the definition of relative retention, and the orthogonal mass result. Copying a minute value from an unrelated chromatogram creates a false non-conformance, or a false pass, without adding identity information about Aib.
References
- PMID:9849822 — Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol — 1998
- PMID:11396951 — Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues — Biochem Biophys Res Commun — 2001
- PMID:30282322 — Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor — Eur J Med Chem — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
